AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30027313 — intervention group
Group type: EXPERIMENTAL
Intervention: FRUCT
Number of subjects: 12
Study 30027313 — intervention group
Group type: EXPERIMENTAL
Intervention: FRUCTEX
Number of subjects: 12
Study 30027313 — intervention group
Group type: COMPARATOR
Intervention: DEX
Number of subjects: 12
Study 28877284 — intervention group
Group type: EXPERIMENTAL
Intervention: Icon infiltrant (DMG)
Number of subjects: 23
Study 28877284 — intervention group
Group type: COMPARATOR
Intervention: Alpha Seal‐DFL (commercial pit‐and‐fissure sealant)
Number of subjects: 23
Study 25251104 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam (PIPC/TAZ) 337.5 mg/kg/day
Number of subjects: 53
Study 25251104 — intervention group
Group type: COMPARATOR
Intervention: Cefepime (CFPM) 100 mg/kg/day
Number of subjects: 53
Study 25251104 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam (PIPC/TAZ)
Number of subjects: 53
Study 25251104 — intervention group
Group type: COMPARATOR
Intervention: Cefepime (CFPM)
Number of subjects: 53
Study 23812801 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal application of 500 μL of Fresh seminal plasma
Number of subjects: 230
Study 23812801 — intervention group
Group type: COMPARATOR
Intervention: Culture medium (placebo)
Number of subjects: 230
Study 21272844 — intervention group
Group type: EXPERIMENTAL
Intervention: Day-case laparoscopic supracervical hysterectomy
Number of subjects: 49
Study 21272844 — intervention group
Group type: COMPARATOR
Intervention: Overnight hospital stay after laparoscopic supracervical hysterectomy
Number of subjects: 49
Study 19851122 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored, four-visit, in-home symptom-focused diabetes intervention
Number of subjects: 180
Study 19851122 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored, four-visit, in-home symptom-focused diabetes intervention with booster telephone calls
Number of subjects: 180
Study 19851122 — intervention group
Group type: COMPARATOR
Intervention: Attentional control focused on skills training for weight management and diet
Number of subjects: 180
Study 15818287 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin (10 mg/kg of body weight once daily for 10 days)
Number of subjects: 413
Study 15818287 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate (45/6.4 mg/kg/d in 2 divided doses for 10 days)
Number of subjects: 413
Study 15818287 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin
Number of subjects: 413
Study 15818287 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate
Number of subjects: 413
Study 14570093 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive care and whole-brain radiotherapy (WBRT)
Number of subjects: 0
Study 14570093 — intervention group
Group type: COMPARATOR
Intervention: Supportive care alone
Number of subjects: 0
Study 10472216 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse contour analysis (PCCO)
Number of subjects: 26
Study 10472216 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous thermodilution technique (CCO)
Number of subjects: 26
Study 10472216 — intervention group
Group type: COMPARATOR
Intervention: Intermittent bolus thermodilution technique (BCO)
Number of subjects: 26
Study 10163467 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate vitrectomy
Number of subjects: 420
Study 10163467 — intervention group
Group type: COMPARATOR
Intervention: Tap and biopsy with no systemic antibiotics
Number of subjects: 420
Study 10163467 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic antibiotics (ceftazidime and amikacin)
Number of subjects: 420
Study 10163467 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with light-perception-only visual acuity
Number of subjects: 420
Study 10163467 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with hand motion acuity or better
Number of subjects: 420
Study 1908138 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure ventilation
Number of subjects: 20
Study 1908138 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control)
Number of subjects: 20
Study 6619027 — intervention group
Group type: EXPERIMENTAL
Intervention: Azlocillin
Number of subjects: 44
Study 6619027 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin
Number of subjects: 44
Study 30430338 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% hydrogen peroxide whitening strips (Crest® 3D Whitestrips® premium plus)
Number of subjects: 113
Study 30430338 — intervention group
Group type: COMPARATOR
Intervention: Control group (non‐whitening strip exposed)
Number of subjects: 113
Study 28922091 — intervention group
Group type: EXPERIMENTAL
Intervention: Information
Number of subjects: 443
Study 28922091 — intervention group
Group type: EXPERIMENTAL
Intervention: Information and Support
Number of subjects: 443
Study 28922091 — intervention group
Group type: EXPERIMENTAL
Intervention: Information, Support, and Coaching (Full CHESS)
Number of subjects: 443
Study 28922091 — intervention group
Group type: EXPERIMENTAL
Intervention: Full CHESS and Mentor
Number of subjects: 443
Study 26160149 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-managed exercise programme
Number of subjects: 86
Study 26160149 — intervention group
Group type: COMPARATOR
Intervention: Usual physiotherapy treatment
Number of subjects: 86
Study 23551623 — intervention group
Group type: EXPERIMENTAL
Intervention: ANKYLOS plus® implants (A-implants)
Number of subjects: 18
Study 23551623 — intervention group
Group type: COMPARATOR
Intervention: Certain® PREVAIL(TM) (B-implants)
Number of subjects: 18
Study 23739317 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous platelet rich fibrin
Number of subjects: 15
Study 23739317 — intervention group
Group type: COMPARATOR
Intervention: Open flap debridement alone
Number of subjects: 15
Study 19708635 — intervention group
Group type: EXPERIMENTAL
Intervention: C4‐5 facet joint injection
Number of subjects: 89
Study 19708635 — intervention group
Group type: COMPARATOR
Intervention: Control group (unilateral multifidi muscle injection)
Number of subjects: 89
Study 18303675 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification and foldable IOL implantation
Number of subjects: 118
Study 18303675 — intervention group
Group type: COMPARATOR
Intervention: Modified tunnel incision non-phacoemulsification and foldable IOL implantation
Number of subjects: 118
Study 15888064 — intervention group
Group type: EXPERIMENTAL
Intervention: cyclosporine‐mycophenolate mofetil (n = 85)
Number of subjects: 239
Study 15888064 — intervention group
Group type: EXPERIMENTAL
Intervention: high‐level tacrolimus (TAC) (8‐12 ng/mL)‐low‐level sirolimus (SRL) (3‐7 ng/mL) (n = 72)
Number of subjects: 239
Study 15888064 — intervention group
Group type: EXPERIMENTAL
Intervention: low‐level TAC (3‐7 ng/mL)‐high‐level SRL (8‐12 ng/mL) (n = 82)
Number of subjects: 239
Study 15888064 — intervention group
Group type: COMPARATOR
Intervention: SRL-treated recipients
Number of subjects: 239
Study 11923699 — intervention group
Group type: EXPERIMENTAL
Intervention: C2 (2-hr post-dose cyclosporine monitoring)
Number of subjects: 307
Study 11923699 — intervention group
Group type: COMPARATOR
Intervention: C0 (conventional trough cyclosporine monitoring)
Number of subjects: 307
Study 11923699 — intervention group
Group type: EXPERIMENTAL
Intervention: C2
Number of subjects: 307
Study 11923699 — intervention group
Group type: COMPARATOR
Intervention: C0
Number of subjects: 307
Study 11923699 — intervention group
Group type: EXPERIMENTAL
Intervention: C2 (patients reaching minimum target CsA levels by day 3)
Number of subjects: 307
Study 9509801 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 7611207 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerulein (10-80 pmol/kg/h) with secretin background (1 CU/kg/h)
Number of subjects: 12
Study 7611207 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline 0.9%)
Number of subjects: 12
Study 2243429 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestipol-niacin therapy
Number of subjects: 162
Study 2243429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 321992 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin and flucloxacillin combination
Number of subjects: 89
Study 321992 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin alone
Number of subjects: 89
Study 31570210 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid (TTA) administered at three points during THA (n=55)
Number of subjects: 102
Study 31570210 — intervention group
Group type: COMPARATOR
Intervention: Saline solution as placebo (Control group, n=47)
Number of subjects: 102
Study 31570210 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 102
Study 31570210 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid administration
Number of subjects: 102
Study 31570210 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher preoperative hemoglobin level
Number of subjects: 102
Study 27644229 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg daily
Number of subjects: 220
Study 27644229 — intervention group
Group type: COMPARATOR
Intervention: Active surveillance
Number of subjects: 220
Study 25745075 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-D
Number of subjects: 1499
Study 25745075 — intervention group
Group type: COMPARATOR
Intervention: ICD
Number of subjects: 1499
Study 23835333 — intervention group
Group type: EXPERIMENTAL
Intervention: Teplizumab
Number of subjects: 52
Study 23835333 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 52
Study 21593295 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 mg, three intravenous infusions)
Number of subjects: 39
Study 21593295 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 19319166 — intervention group
Group type: EXPERIMENTAL
Intervention: Teething
Number of subjects: 225
Study 19319166 — intervention group
Group type: EXPERIMENTAL
Intervention: Childcare attendance
Number of subjects: 225
Study 19319166 — intervention group
Group type: EXPERIMENTAL
Intervention: Having siblings aged less than 5 years
Number of subjects: 225
Study 19319166 — intervention group
Group type: EXPERIMENTAL
Intervention: Total illnesses
Number of subjects: 225
Study 19319166 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory illness (RI)
Number of subjects: 225
Study 15967694 — intervention group
Group type: EXPERIMENTAL
Intervention: ipratropium + theophylline (IP + THEO)
Number of subjects: 60
Study 15967694 — intervention group
Group type: EXPERIMENTAL
Intervention: formoterol + theophylline (FOR + THEO)
Number of subjects: 60
Study 15967694 — intervention group
Group type: EXPERIMENTAL
Intervention: ipratropium + formoterol (IP + FOR)
Number of subjects: 60
Study 12048323 — intervention group
Group type: COMPARATOR
Intervention: HI group (VO2max > 62.5 mL.kg‐1.min‐1)
Number of subjects: 12
Study 10209977 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine
Number of subjects: 404
Study 10209977 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated group
Number of subjects: 404
Study 7843749 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 25 mg
Number of subjects: 86
Study 7843749 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 100 mg
Number of subjects: 86
Study 7843749 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 1 mg
Number of subjects: 86
Study 7843749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 2236726 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine
Number of subjects: 38
Study 2236726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 360853 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined preoperative radiotherapy and surgery
Number of subjects: 100
Study 360853 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 100
Study 29545948 — intervention group
Group type: EXPERIMENTAL
Intervention: Daprodustat (100 mg) coadministered with pioglitazone or rosuvastatin
Number of subjects: 40
Study 29545948 — intervention group
Group type: EXPERIMENTAL
Intervention: Daprodustat (25 mg) coadministered with trimethoprim
Number of subjects: 40
Study 29545948 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim (as a weak CYP2C8 inhibitor)
Number of subjects: 40
Study 27417531 — intervention group
Group type: EXPERIMENTAL
Intervention: CARE+ Spanish intervention
Number of subjects: 494
Study 27417531 — intervention group
Group type: COMPARATOR
Intervention: Risk assessment-only control
Number of subjects: 494
Study 23570834 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized family planning messages and referrals provided by trained vaccinators
Number of subjects: 8892
Study 23570834 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 8892
Study 23765178 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide LAR 20 mg
Number of subjects: 42
Study 23765178 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide LAR 40 mg
Number of subjects: 42
Study 23765178 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide LAR 60 mg
Number of subjects: 42
Study 23765178 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide LAR (all doses)
Number of subjects: 42
Study 19910943 — intervention group
Group type: EXPERIMENTAL
Intervention: CR: 25% decrease in energy intake
Number of subjects: 28
Study 19910943 — intervention group
Group type: EXPERIMENTAL
Intervention: CREX: 12.5% CR + 12.5% increase in energy expenditure
Number of subjects: 28
Study 19910943 — intervention group
Group type: EXPERIMENTAL
Intervention: LCD: low-calorie diet until 15% weight reduction followed by weight maintenance
Number of subjects: 28
Study 19910943 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study 18548292 — intervention group
Group type: EXPERIMENTAL
Intervention: One-visit indirect pulp treatment (IPT)
Number of subjects: 135
Study 18548292 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-visit indirect pulp treatment (IPT)
Number of subjects: 135
Study 18548292 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct complete excavation (DCE)
Number of subjects: 135
Study 15708100 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily tobramycin
Number of subjects: 244
Study 15708100 — intervention group
Group type: COMPARATOR
Intervention: Three-times daily tobramycin
Number of subjects: 244
Study 15708100 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily tobramycin (in children)
Number of subjects: 244
Study 15708100 — intervention group
Group type: COMPARATOR
Intervention: Three-times daily tobramycin (in children)
Number of subjects: 244
Study 12372942 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) 64.6 IU/kg in a single bolus at the start of dialysis
Number of subjects: 54
Study 12372942 — intervention group
Group type: COMPARATOR
Intervention: Standard heparin (SH) 1,500 IU at the start of dialysis and 1,500 +/- 500 IU in continuous infusion
Number of subjects: 54
Study 9502829 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg of pergolide
Number of subjects: 32
Study 9502829 — intervention group
Group type: COMPARATOR
Intervention: 2.5 mg of bromocriptine
Number of subjects: 32
Study 7694914 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (N = 6)
Number of subjects: 12
Study 7694914 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N = 6)
Number of subjects: 12
Study 2708001 — intervention group
Group type: EXPERIMENTAL
Intervention: Resorbable intraperitoneal mesh of polyglactin 910
Number of subjects: 100
Study 2708001 — intervention group
Group type: COMPARATOR
Intervention: Externally applied polyamide fiber mesh
Number of subjects: 100
Study 329825 — intervention group
Group type: EXPERIMENTAL
Intervention: Practolol (400 mg/day)
Number of subjects: 31
Study 329825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 31711467 — intervention group
Group type: EXPERIMENTAL
Intervention: Social networking time
Number of subjects: 765
Study 31711467 — intervention group
Group type: EXPERIMENTAL
Intervention: Personality traits (emotional instability, extraversion, conscientiousness)
Number of subjects: 765
Study 31711467 — intervention group
Group type: EXPERIMENTAL
Intervention: Big Five personality traits
Number of subjects: 765
Study 28711309 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalpel-designed bevel needle (SB)
Number of subjects: 150
Study 28711309 — intervention group
Group type: COMPARATOR
Intervention: Triple bevel needle (TB)
Number of subjects: 150
Study 28711309 — intervention group
Group type: COMPARATOR
Intervention: Regular bevel needle (RB)
Number of subjects: 150
Study 28711309 — intervention group
Group type: EXPERIMENTAL
Intervention: All needle types (SB, TB, RB)
Number of subjects: 150
Study 25849646 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (40 mg daily) with NaCl supplementation (100 mmol/24 h)
Number of subjects: 28
Study 25849646 — intervention group
Group type: COMPARATOR
Intervention: Telmisartan (40 mg daily) with placebo
Number of subjects: 28
Study 25166287 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive medication management services delivered postdischarge
Number of subjects: 0
Study 25166287 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 22559376 — intervention group
Group type: EXPERIMENTAL
Intervention: MAP with best masked MDTs
Number of subjects: 0
Study 22559376 — intervention group
Group type: COMPARATOR
Intervention: MAP with worst masked MDTs
Number of subjects: 0
Study 19387825 — intervention group
Group type: EXPERIMENTAL
Intervention: Wellness program focusing on stress management and problem solving
Number of subjects: 0
Study 19387825 — intervention group
Group type: EXPERIMENTAL
Intervention: Broader wellness intervention
Number of subjects: 0
Study 19387825 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 17498002 — intervention group
Group type: EXPERIMENTAL
Intervention: 22-oxacalcitriol
Number of subjects: 23
Study 17498002 — intervention group
Group type: COMPARATOR
Intervention: Calcitriol
Number of subjects: 23
Study 15448489 — intervention group
Group type: EXPERIMENTAL
Intervention: Keratoconus index (KI) calculated from peripheral corneal thickness (PCT) to thinnest corneal thickness (TCT) using a computer-assisted procedure after ultrabiomicroscope (UBM) examination.
Number of subjects: 60
Study 15448489 — intervention group
Group type: EXPERIMENTAL
Intervention: Keratoconus severity index (KSI) obtained by videokeratography.
Number of subjects: 60
Study 15448489 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between KI and KSI.
Number of subjects: 60
Study 11166966 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine (0.1 to 10 microM)
Number of subjects: 10
Study 11166966 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine (0.1 to 10 microM)
Number of subjects: 10
Study 11166966 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine (0.01 to 1 microM)
Number of subjects: 10
Study 11166966 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 10
Study 11166966 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprathreshold heat stimulus (47 degrees C, 2 s)
Number of subjects: 10
Study 11166966 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin II and vasopressin (non-adrenergic vasoconstrictors)
Number of subjects: 10
Study 11166966 — intervention group
Group type: COMPARATOR
Intervention: Blood pressure cuff occlusion
Number of subjects: 10
Study 9539899 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with oral conjugated oestrogens (0.625 mg daily) and cyclic medroxyprogesterone acetate (10 mg daily on Day 14‐27 of each menstrual cycle)
Number of subjects: 105
Study 9539899 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 105
Study 9539899 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 105
Study 8005124 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril pretreatment
Number of subjects: 30
Study 31705691 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (i.m.) administration of tolfenamic acid (4 mg/kg body weight)
Number of subjects: 10
Study 31705691 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (i.v.) administration of tolfenamic acid (4 mg/kg body weight)
Number of subjects: 10
Study 29704955 — intervention group
Group type: EXPERIMENTAL
Intervention: Plate osteosynthesis (group A, n=36)
Number of subjects: 69
Study 29704955 — intervention group
Group type: COMPARATOR
Intervention: Non-operative management (arm pouch, group B, n=33)
Number of subjects: 69
Study 27183077 — intervention group
Group type: EXPERIMENTAL
Intervention: Ridge-splitting procedure (test group)
Number of subjects: 10
Study 27183077 — intervention group
Group type: COMPARATOR
Intervention: Conventional drilling procedure (control group)
Number of subjects: 10
Study 27183077 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 10
Study 25416143 — intervention group
Group type: COMPARATOR
Intervention: Invisalign group (IG)
Number of subjects: 145
Study 25416143 — intervention group
Group type: EXPERIMENTAL
Intervention: Edgewise group (EG)
Number of subjects: 145
Study 25416143 — intervention group
Group type: COMPARATOR
Intervention: Edgewise and Invisalign group (EIG)
Number of subjects: 145
Study 23361051 — intervention group
Group type: EXPERIMENTAL
Intervention: Trebananib (10 mg/kg once weekly) plus FOLFIRI
Number of subjects: 144
Study 23361051 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus FOLFIRI
Number of subjects: 144
Study 20083537 — intervention group
Group type: EXPERIMENTAL
Intervention: DAS28 measurement by a nurse prior to rheumatologist visit
Number of subjects: 248
Study 20083537 — intervention group
Group type: COMPARATOR
Intervention: Usual care (DAS28 measured but not provided to rheumatologists)
Number of subjects: 248
Study 20083537 — intervention group
Group type: EXPERIMENTAL
Intervention: DAS28 measurement by a nurse
Number of subjects: 248
Study 20083537 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 248
Study 20083537 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline DAS28
Number of subjects: 248
Study 20083537 — intervention group
Group type: EXPERIMENTAL
Intervention: HAQ
Number of subjects: 248
Study 19919919 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal microdialysis
Number of subjects: 45
Study 19919919 — intervention group
Group type: COMPARATOR
Intervention: Control group (38 patients with uncomplicated postoperative course)
Number of subjects: 45